×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP ...
PR Newswire
PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on...
2 hours ago
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in ...
KXAN Austin
CRANBURY, N.J., April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing...
2 days ago
Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643
MarketWatch
By Chris Wack Palatin Technologies shares were up 27% to $2.24 after the company said it saw positive topline results for its Phase 3...
3 weeks ago
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript
Yahoo Finance
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings...
2 months ago
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American ...
PR Newswire
Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical...
3 weeks ago
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
Yahoo Finance
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial,...
3 weeks ago
Palatin Technologies Shares Jump After Database Lock of Dry Eye Disease Drug Study
MarketWatch
By Zaeem Shoaib Shares of Palatin Technologies rose after the company announced that the database had been locked for the data of its phase...
2 months ago
Palatin Technologies (NYSEAMERICAN:PTN) Shares Cross Above Two Hundred Day Moving Average of $0.00
Defense World
Read Palatin Technologies (NYSEAMERICAN:PTN) Shares Cross Above Two Hundred Day Moving Average of $0.00 at Defense World.
4 days ago
Palatin to push through with dry eye therapy despite Phase III miss
Clinical Trials Arena
Palatin's dry eye therapy PL9643 failed to meet endpoints in the Phase III trial without statistical adjustments.
2 months ago
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
PR Newswire
PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on...
4 months ago